TIBCO Software Inc. announced the launch of TIBCO Spotfire® Clinical, providing an in-memory, analytics platform on the market that aims to allow clinical development teams to make faster and more accurate decisions. Through visual and interactive exploration of clinical data, Spotfire Clinical® will enable actionable decisions that enhance patient safety, streamline operations and accelerate time to market for new medications and devices.
Clinical development teams can visualize and interact with operational, clinical and safety data in a single interface to support forward-looking decisions. By leveraging the new integrated S+/R statistics and predictive analytics capabilities of the TIBCO Spotfire® Analytics Platform, users will be able to conduct advanced what-if scenarios and analysis to gain insights into data, without the intervention of IT resources or biostatisticians.
“We use TIBCO Spotfire software for analyzing and reviewing operational and medical data on all our clinical trials,” said John Keilty vice president of IT and Informatics, Infinity Pharmaceuticals. “With Spotfire, all our clinical, safety and operational data are available in real time. This enables us to shorten the time between critical development gates, and to meet key milestones sooner while simultaneously managing safety risk.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.